Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

72.250
+1.7502.48%
Volume:379.38K
Turnover:27.23M
Market Cap:39.23B
PE:47.86
High:72.950
Open:69.200
Low:69.200
Close:70.500
52wk High:92.000
52wk Low:20.600
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:0.12
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.510
ROE:27.54%
ROA:4.97%
PB:10.16
PE(LYR):47.86
PS:5.97

Loading ...

Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum

Simply Wall St.
·
Feb 16

Shanghai Henlius Biotech, Inc. (2696) Announces FDA Approval of HLX15-SC IND for Multiple Myeloma

Bulletin Express
·
Feb 16

HENLIUS's HLX15-SC for Multiple Myeloma Receives FDA Clearance for Phase 1 Trial

Stock News
·
Feb 16

FDA Approves IND Application for Shanghai Henlius Biotech HLX15-SC in Multiple Myeloma

Reuters
·
Feb 16

Shanghai Henlius Biotech - FDA Approves Ind Application for Hlx15-Sc for Multiple Myeloma

THOMSON REUTERS
·
Feb 16

Shanghai Henlius Biotech, Inc. (2696) Announces NMPA Approval for HLX15-SC IND in Multiple Myeloma

Bulletin Express
·
Feb 12

Shanghai Henlius Biotech Inc - Investigational New Drug Application of Hlx15-Sc for Treatment of Multiple Myeloma Approved by Nmpa

THOMSON REUTERS
·
Feb 12

Shanghai Henlius Biotech Receives NMPA Approval for HLX15-SC IND Application

Reuters
·
Feb 12

Shanghai Henlius Biotech (2696) Announces First Patient Dosed in HLX43 Combination Trial for Advanced Colorectal Cancer

Bulletin Express
·
Feb 11

HENLIUS (02696) Doses First Patient in China for Phase 1b/2 Trial of HLX43 Combined with HLX07 or Hansizhuang® in Advanced/Metastatic Colorectal Cancer

Stock News
·
Feb 11

Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer

Reuters
·
Feb 11

HENLIUS Shares Surge Over 6% Again, Climbing More Than 24% This Month on Japanese Rights Deal for Serplulimab

Stock News
·
Feb 10

Goldman Sachs: Mainland Healthcare Sector Returns to Hinge on Data and Earnings Visibility This Year, CDMO Firms Favored

Stock News
·
Feb 09

HENLIUS Shares Climb Over 5% on Licensing Deal with Eisai for Japan Rights

Stock News
·
Feb 06

Eisai and Henlius Enter Into Exclusive Commercial License Agreement for Anti-Pd-1 Antibody Serplulimab in Japan

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech Inc - Plans 2026 Application for Es-Sclc in Japan

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech (2696) and Eisai Sign License Agreement for HANSIZHUANG in Japan

Bulletin Express
·
Feb 05

Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment

Stock News
·
Feb 05

Shanghai Henlius Biotech schließt Lizenzvereinbarung mit Eisai für Hansizhuang in Japan

Reuters
·
Feb 05

Shanghai Henlius Biotech - Granted Eisai Co License to Develop, Manufacture & Commercialise Hansizhuang

THOMSON REUTERS
·
Feb 05